TrkC signaling is activated in adenoid cystic carcinoma and requires NT-3 to stimulate invasive behavior

Oncogene

Volumn 32, Issue 32, 2013, Pages 3698-3710

  Ivanov, S V ^a   Panaccione, A ^a,b   Brown, B ^b   Guo, Y ^b   Moskaluk, C A ^c   Wick, M J ^d   Brown, J L ^e   Ivanova, A V ^a   Issaeva, N ^a   El Naggar, A K ^f   Yarbrough, W G ^a,g,h  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d South Texas Accelerated Research Therapeutics   (United States)

^e ASTRAZENECA   (United Kingdom)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g Smilow Cancer Hospital   (United States)

^h YALE CANCER CENTER   (United States)

Author keywords

Bcl2; invasion; migration; neurotrophin 3; salivary adenoid cystic carcinoma; TrkC

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NEUROTROPHIN 3 RECEPTOR; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P53; RAS PROTEIN; VASCULOTROPIN RECEPTOR 1;

ADENOID CYSTIC CARCINOMA; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CELL FUNCTION; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CHEMOTAXIS; CLINICAL ARTICLE; COLONY FORMATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOSKELETON; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION PROFILING; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; MYOEPITHELIUM CELL; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SALIVARY GLAND CARCINOMA; SIGNAL TRANSDUCTION; STIMULATION;

ANIMALS; CARCINOMA, ADENOID CYSTIC; CELL LINE, TUMOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; MICE; NEOPLASM INVASIVENESS; NEUROTROPHIN 3; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; RAS PROTEINS; RECEPTOR, TRKC; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; WNT SIGNALING PATHWAY;

MUS;

EID: 84881474156     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.377     Document Type: Article

References (69)

1. Fitzpatrick PJ, Theriault C. Malignant salivary gland tumors. Int J Radiat Oncol Biol Phys 1986; 12: 1743-1747.
2. Chummun S, McLean NR, Kelly CG, Dawes PJ, Meikle D, Fellows S et al. Adenoid cystic carcinoma of the head and neck. Br J Plast Surg 2001; 54: 476-480.
3. Phuchareon J, Ohta Y, Woo JM, Eisele DW, Tetsu O. Genetic profiling reveals crosscontamination and misidentification of 6 adenoid cystic carcinoma cell lines: ACC2, ACC3, ACCM, ACCNS, ACCS and CAC2. PLoS One 2009; 4: e6040.
4. Harel L, Costa B, Fainzilber M. On the death Trk. Dev Neurobiol 2010; 70: 298-303.
5. Denkins Y, Reiland J, Roy M, Sinnappah-Kang ND, Galjour J, Murry BP et al. Brain metastases in melanoma: roles of neurotrophins. Neuro Oncol 2004; 6: 154-165.
6. Jin W, Kim GM, Kim MS, Lim MH, Yun C, Jeong J et al. TrkC plays an essential role in breast tumor growth and metastasis. Carcinogenesis 2010; 31: 1939-1947.
7. Wang T, Yu D, Lamb ML. Trk kinase inhibitors as new treatments for cancer and pain. Expert Opin Ther Pat 2009; 19: 305-319.
8. Kumar S, Kahn MA, Dinh L, de Vellis J. NT-3-mediated TrkC receptor activation promotes proliferation and cell survival of rodent progenitor oligodendrocyte cells in vitro and in vivo. J Neurosci Res 1998; 54: 754-765.
9. Postigo A, Calella AM, Fritzsch B, Knipper M, Katz D, Eilers A et al. Distinct requirements for TrkB and TrkC signaling in target innervation by sensory neurons. Genes Dev 2002; 16: 633-645.
10. Barnabe-Heider F, Miller FD. Endogenously produced neurotrophins regulate survival and differentiation of cortical progenitors via distinct signaling pathways. J Neurosci 2003; 23: 5149-5160.
11. Bartkowska K, Paquin A, Gauthier AS, Kaplan DR, Miller FD. Trk signaling regulates neural precursor cell proliferation and differentiation during cortical development. Development 2007; 134: 4369-4380.
12. Nikoletopoulou V, Lickert H, Frade JM, Rencurel C, Giallonardo P, Zhang L et al. Neurotrophin receptors TrkA and TrkC cause neuronal death whereas TrkB does not. Nature 2010; 467: 59-63.
13. Fernandez RM, Sanchez-Mejias A, Mena MD, Ruiz-Ferrer M, Lopez-Alonso M, Antinolo G et al. A novel point variant in NTRK3, R645C, suggests a role of this gene in the pathogenesis of Hirschsprung disease. Ann Hum Genet 2009; 73: 19-25.
14. Sanchez-Mejias A, Fernandez RM, Lopez-Alonso M, Antinolo G, Borrego S. Contribution of RET, NTRK3 and EDN3 to the expression of Hirschsprung disease in a multiplex family. J Med Genet 2009; 46: 862-864.
15. Tauszig-Delamasure S, Bouzas-Rodriguez J. Targeting neurotrophin-3 and its dependence receptor tyrosine kinase receptor C: a new antitumoral strategy. Expert Opin Ther Targets 2011; 15: 847-858.
16. Bouzas-Rodriguez J, Cabrera JR, Delloye-Bourgeois C, Ichim G, Delcros JG, Raquin MA et al. Neurotrophin-3 production promotes human neuroblastoma cell survival by inhibiting TrkC-induced apoptosis. J Clin Invest 2010; 120: 850-858.
17. Wood LD, Calhoun ES, Silliman N, Ptak J, Szabo S, Powell SM et al. Somatic mutations of GUCY2F, EPHA3, and NTRK3 in human cancers. Hum Mutat 2006; 27: 1060-1061.
18. Lannon CL, Sorensen PH. ETV6-NTRK3: a chimeric protein tyrosine kinase with transformation activity in multiple cell lineages. Semin Cancer Biol 2005; 15: 215-223.
19. Bardelli A, Parsons DW, Silliman N, Ptak J, Szabo S, Saha S et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 2003; 300: 949.
20. Davies H, Hunter C, Smith R, Stephens P, Greenman C, Bignell G et al. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 2005; 65: 7591-7595.
21. Stephens P, Edkins S, Davies H, Greenman C, Cox C, Hunter C et al. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet 2005; 37: 590-592.
22. Knezevich SR, McFadden DE, Tao W, Lim JF, Sorensen PH. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet 1998; 18: 184-187.
23. Tognon C, Knezevich SR, Huntsman D, Roskelley CD, Melnyk N, Mathers JA et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2002; 2: 367-376.
24. Skalova A, Vanecek T, Sima R, Laco J, Weinreb I, Perez-Ordonez B et al. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol 2010; 34: 599-608.
25. Kruttgen A, Schneider I, Weis J. The dark side of the NGF family: neurotrophins in neoplasias. Brain Pathol 2006; 16: 304-310.
26. Sinnappah-Kang ND, Kaiser AJ, Blust BE, Mrak RE, Marchetti D. Heparanase TrkC and p75NTR: their functional involvement in human medulloblastoma cell invasion. Int J Oncol 2005; 27: 617-626.
27. Marchetti D, Mrak RE, Paulsen DD, Sinnappah-Kang ND. Neurotrophin receptors and heparanase: a functional axis in human medulloblastoma invasion. J Exp Clin Cancer Res 2007; 26: 5-23.
28. Jin W, Yun C, Jeong J, Park Y, Lee HD, Kim SJ. c-Src is required for tropomyosin receptor kinase C (TrkC)-induced activation of the phosphatidylinositol 3-kinase (PI3K)-AKT pathway. J Biol Chem 2008; 283: 1391-1400.
29. Sakamoto Y, Kitajima Y, Edakuni G, Sasatomi E, Mori M, Kitahara K et al. Expression of Trk tyrosine kinase receptor is a biologic marker for cell proliferation and perineural invasion of human pancreatic ductal adenocarcinoma. Oncol Rep 2001; 8: 477-484.
30. Wang T, Lamb ML, Scott DA, Wang H, Block MH, Lyne PD et al. Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases. J Med Chem 2008; 51: 4672-4684.
31. Buzanska L, Zychowicz M, Ruiz A, Ceriotti L, Coecke S, Rauscher H et al. Neural stem cells from human cord blood on bioengineered surfaces-novel approach to multiparameter bio-tests. Toxicology 2010; 270: 35-42.
32. Marino S. Medulloblastoma: developmental mechanisms out of control. Trends Mol Med 2005; 11: 17-22.
33. Katoh M. Network of WNT and other regulatory signaling cascades in pluripotent stem cells and cancer stem cells. Curr Pharm Biotechnol 2011; 12: 160-170.
34. Kelsh RN. Sorting out Sox10 functions in neural crest development. Bioessays 2006; 28: 788-798.
35. Wu SM, Choo AB, Yap MG, Chan KK. Role of Sonic hedgehog signaling and the expression of its components in human embryonic stem cells. Stem Cell Res 2010; 4: 38-49.
36. Bohm J, Buck A, Borozdin W, Mannan AU, Matysiak-Scholze U, Adham I et al. Sall1, sall2, and sall4 are required for neural tube closure in mice. Am J Pathol 2008; 173: 1455-1463.
37. Katayama K, Zine A, Ota M, Matsumoto Y, Inoue T, Fritzsch B et al. Disorganized innervation and neuronal loss in the inner ear of Slitrk6-deficient mice. PLoS One 2009; 4: e7786.
38. Fagiani E, Giardina G, Luzi L, Cesaroni M, Quarto M, Capra M et al. RaLP, a new member of the Src homology and collagen family, regulates cell migration and tumor growth of metastatic melanomas. Cancer Res 2007; 67: 3064-3073.
39. Sundram U, Harvell JD, Rouse RV, Natkunam Y. Expression of the B-cell proliferation marker MUM1 by melanocytic lesions and comparison with S100, gp100 (HMB45), and MelanA. Mod Pathol 2003; 16: 802-810.
40. Moskaluk CA, Baras AS, Mancuso SA, Fan H, Davidson RJ, Dirks DC et al. Development and characterization of xenograft model systems for adenoid cystic carcinoma. Lab Invest 2011; 91: 1480-1490.
41. Labouyrie E, Dubus P, Groppi A, Mahon FX, Ferrer J, Parrens M et al. Expression of neurotrophins and their receptors in human bone marrow. Am J Pathol 1999; 154: 405-415.
42. Marchetti D, Denkins Y, Reiland J, Greiter-Wilke A, Galjour J, Murry B et al. Brainmetastatic melanoma: a neurotrophic perspective. Pathol Oncol Res 2003; 9: 147-158.
43. Huang EJ, Reichardt LF. Trk receptors: roles in neuronal signal transduction. Annu Rev Biochem 2003; 72: 609-642.
44. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 2011; 11: 761-774.
45. Goldberg L, Kloog YA. Ras inhibitor tilts the balance between Rac and Rho and blocks phosphatidylinositol 3-kinase-dependent glioblastoma cell migration. Cancer Res 2006; 66: 11709-11717.
46. Edsjo A, Hallberg B, Fagerstrom S, Larsson C, Axelson H, Pahlman S. Differences in early and late responses between neurotrophin-stimulated trkA-and trkC-transfected SH-SY5Y neuroblastoma cells. Cell Growth Differ 2001; 12: 39-50.
47. Jaglin XH, Poirier K, Saillour Y, Buhler E, Tian G, Bahi-Buisson N et al. Mutations in the beta-tubulin gene TUBB2B result in asymmetrical polymicrogyria. Nat Genet 2009; 41: 746-752.
48. Medjkane S, Perez-Sanchez C, Gaggioli C, Sahai E, Treisman R. Myocardin-related transcription factors and SRF are required for cytoskeletal dynamics and experimental metastasis. Nat Cell Biol 2009; 11: 257-268.
49. Rottner K, Hanisch J, Campellone KG. WASH, WHAMM and JMY: regulation of Arp2/3 complex and beyond. Trends Cell Biol 2010; 20: 650-661.
50. Rajan N, Elliott R, Clewes O, Mackay A, Reis-Filho JS, Burn J et al. Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours. Oncogene 2011; 30: 4243-4260.
51. Dardick I, van Nostrand AW. Myoepithelial cells in salivary gland tumors-revisited. Head Neck Surg 1985; 7: 395-408.
52. Zandi R, Larsen AB, Andersen P, Stockhausen MT, Poulsen HS. Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal 2007; 19: 2013-2023.
53. Mehlen P. Dependence receptors: the trophic theory revisited. Sci Signal 2010; 3: pe47.
54. Montano X. P53 associates with trk tyrosine kinase. Oncogene 1997; 15: 245-256.
55. Aloyz RS, Bamji SX, Pozniak CD, Toma JG, Atwal J, Kaplan DR et al. p53 is essential for developmental neuron death as regulated by the TrkA and p75 neurotrophin receptors. J Cell Biol 1998; 143: 1691-1703.
56. Lavoie JF, Lesauteur L, Kohn J, Wong J, Furtoss O, Thiele CJ et al. TrkA induces apoptosis of neuroblastoma cells and does so via a p53-dependent mechanism. J Biol Chem 2005; 280: 29199-29207.
57. Montano X. Repression of SHP-1 expression by p53 leads to trkA tyrosine phosphorylation and suppression of breast cancer cell proliferation. Oncogene 2009; 28: 3787-3800.
58. Frenzel A, Grespi F, Chmelewskij W, Villunger A. Bcl2 family proteins in carcinogenesis and the treatment of cancer. Apoptosis 2009; 14: 584-596.
59. Kummoona R, Mohammad Sami S, Al-Kapptan I, Al-Muala H. Study of antiapoptotic gene of oral carcinoma by using Bcl-2 oncogene. J Oral Pathol Med 2008; 37: 345-351.
60. Jao W, Keh PC, Swerdlow MA. Ultrastructure of the basal cell adenoma of parotid gland. Cancer 1976; 37: 1322-1333.
61. Regezi JA, Batsakis JG. Histogenesis of salivary gland neoplasms. Otolaryngol Clin North Am 1977; 10: 297-307.
62. Azevedo RS, de Almeida OP, Kowalski LP, Pires FR. Comparative cytokeratin expression in the different cell types of salivary gland mucoepidermoid carcinoma. Head Neck Pathol 2008; 2: 257-264.
63. Hubner G, Klein HJ, Kleinsasser O, Schiefer HG. Role of myoepithelial cells in the development of salivary gland tumors. Cancer 1971; 27: 1255-1261.
64. Hardy G, Kramer B. The myoepithelium of human major salivary glands revisited. SADJ 1998; 53: 371-375.
65. Slebos RJ, Yi Y, Ely K, Carter J, Evjen A, Zhang X et al. Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res 2006; 12: 3 Pt 1 701-709.
66. Zhang B, Kirov S, Snoddy J. WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res 2005; 33(Web Server issue): W741-W74.
67. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550.
68. Reimand J, Arak T, Vilo J. :Profiler-a web server for functional interpretation of gene lists (2011 update). Nucleic Acids Res 2011; 39: (Web Server issue): W307-W315.
69. Ivanova AV, Goparaju CM, Ivanov SV, Nonaka D, Cruz C, Beck A et al. Protumorigenic role of HAPLN1 and its IgV domain in malignant pleural mesothelioma. Clin Cancer Res 2009; 15: 2602-2611.